We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investigational Treatments for Epidermolysis Bullosa.
- Authors
Hou, Ping-Chen; Wang, Han-Tang; Abhee, Stasha; Tu, Wei-Ting; McGrath, John A.; Hsu, Chao-Kai
- Abstract
Epidermolysis bullosa (EB) is a heterogeneous group of rare inherited blistering skin disorders characterized by skin fragility following minor trauma, usually present since birth. EB can be categorized into four classical subtypes, EB simplex, junctional EB, dystrophic EB and Kindler EB, distinguished on clinical features, plane of blister formation in the skin, and molecular pathology. Treatment for EB is mostly supportive, focusing on wound care and patient symptoms such as itch or pain. However, therapeutic advances have also been made in targeting the primary genetic abnormalities as well as the secondary inflammatory footprint of EB. Pre-clinical or clinical testing of gene therapies (gene replacement, gene editing, RNA-based therapy, natural gene therapy), cell-based therapies (fibroblasts, bone marrow transplantation, mesenchymal stromal cells, induced pluripotential stem cells), recombinant protein therapies, and small molecule and drug repurposing approaches, have generated new hope for better patient care. In this article, we review advances in translational research that are impacting on the quality of life for people living with different forms of EB and which offer hope for improved clinical management.
- Subjects
HUMAN abnormality genetics; SKIN diseases; CELLULAR therapy; INVESTIGATIONAL drugs; GENETIC testing; GENETIC disorders; MOLECULAR pathology; DRUG design; MEDICAL care; PATIENTS; BLISTERS; GENE therapy; QUALITY of life; EPIDERMOLYSIS bullosa; DRUG development; WOUND care; RECOMBINANT proteins; DISEASE management; SYMPTOMS
- Publication
American Journal of Clinical Dermatology, 2021, Vol 22, Issue 6, p801
- ISSN
1175-0561
- Publication type
Article
- DOI
10.1007/s40257-021-00626-3